BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 36468774)

  • 1. The cancer epigenome: Non-cell autonomous player in tumor immunity.
    Kato S; Maeda Y; Sugiyama D; Watanabe K; Nishikawa H; Hinohara K
    Cancer Sci; 2023 Mar; 114(3):730-740. PubMed ID: 36468774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
    Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
    Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy.
    Tuccitto A; Shahaj E; Vergani E; Ferro S; Huber V; Rodolfo M; Castelli C; Rivoltini L; Vallacchi V
    Virchows Arch; 2019 Apr; 474(4):407-420. PubMed ID: 30374798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.
    Loo Yau H; Ettayebi I; De Carvalho DD
    Trends Cell Biol; 2019 Jan; 29(1):31-43. PubMed ID: 30153961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulation and therapeutic targets in the tumor microenvironment.
    Xie Z; Zhou Z; Yang S; Zhang S; Shao B
    Mol Biomed; 2023 Jun; 4(1):17. PubMed ID: 37273004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The follicular lymphoma epigenome regulates its microenvironment.
    Amin R; Braza MS
    J Exp Clin Cancer Res; 2022 Jan; 41(1):21. PubMed ID: 35022084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intimate communications within the tumor microenvironment: stromal factors function as an orchestra.
    Cheng B; Yu Q; Wang W
    J Biomed Sci; 2023 Jan; 30(1):1. PubMed ID: 36600243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies.
    Baxevanis CN; Fortis SP; Perez SA
    Semin Cancer Biol; 2021 Jul; 72():76-89. PubMed ID: 31881337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities.
    Tien FM; Lu HH; Lin SY; Tsai HC
    J Biomed Sci; 2023 Jan; 30(1):3. PubMed ID: 36627707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the RNA m
    Li X; Ma S; Deng Y; Yi P; Yu J
    Mol Cancer; 2022 Mar; 21(1):76. PubMed ID: 35296338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Janus Face of Tumor Microenvironment Targeted by Immunotherapy.
    Buoncervello M; Gabriele L; Toschi E
    Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity.
    Davies A; Zoubeidi A; Beltran H; Selth LA
    Cancer Discov; 2023 Aug; 13(8):1771-1788. PubMed ID: 37470668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer.
    Hargadon KM
    Cell Mol Life Sci; 2023 Jan; 80(2):40. PubMed ID: 36629955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of Immune Cells in the Tumor Microenvironment.
    Jung JG; Le A
    Adv Exp Med Biol; 2021; 1311():173-185. PubMed ID: 34014543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
    Phuengkham H; Ren L; Shin IW; Lim YT
    Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications.
    Li Y; Wu Y; Hu Y
    Front Immunol; 2021; 12():641883. PubMed ID: 33927716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment.
    Zhang J; Tavakoli H; Ma L; Li X; Han L; Li X
    Adv Drug Deliv Rev; 2022 Aug; 187():114365. PubMed ID: 35667465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of antitumor immunity by inflammation-induced epigenetic alterations.
    Karin M; Shalapour S
    Cell Mol Immunol; 2022 Jan; 19(1):59-66. PubMed ID: 34465885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance.
    Jiang T; Chen X; Ren X; Yang JM; Cheng Y
    Drug Resist Updat; 2021 May; 56():100752. PubMed ID: 33765484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.